CagriSema (Cagrilintide + Semaglutide), Research Reference

CagriSema is an investigational combination product developed by Novo Nordisk consisting of cagrilintide 2.4 mg, a long-acting amylin analogue, co-administered with semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist, both delivered as a single weekly subcutaneous injection. Research has investigated this dual-agonist combination for its potential to produce greater body weight reduction than either component alone by engaging two distinct but convergent appetite-regulating receptor systems.

Quick Reference

Overview

CagriSema combines two pharmacologically distinct peptides into a single co-formulated subcutaneous injection administered once weekly. The two components are:

Cagrilintide is a synthetic long-acting amylin analogue. Amylin is a 37-amino acid peptide co-secreted alongside insulin from pancreatic beta cells in response to food intake. Native amylin has a very short plasma half-life, limiting its therapeutic utility. Cagrilintide achieves an approximately 7-day half-life through fatty acid conjugation, analogous to the albumin-binding strategy applied to semaglutide. Cagrilintide acts on amylin receptors (AMY1, AMY2, and AMY3) in the hypothalamus and area postrema.

Semaglutide is a GLP-1 receptor agonist also used as the active ingredient in Ozempic (approved for type 2 diabetes management) and Wegovy (approved for chronic weight management in adults). In CagriSema, semaglutide is used at the 2.4 mg weekly dose, the same as Wegovy.

As of 2026, semaglutide 2.4 mg (Wegovy) and semaglutide 0.5 to 2 mg (Ozempic) have received regulatory approval in multiple jurisdictions individually. Cagrilintide has not received independent regulatory approval. CagriSema as a combination product has not received regulatory approval in any market and remains investigational, with Phase 3 REDEFINE trials ongoing and regulatory filings anticipated following their completion.

Mechanism of Action

GLP-1 Receptor Agonism (Semaglutide Component)

Semaglutide activates glucagon-like peptide-1 receptors expressed throughout the central nervous system, including the arcuate nucleus and nucleus tractus solitarius in the hypothalamus and brainstem. Research has characterised the primary weight-relevant effects as:

• Appetite suppression through hypothalamic signalling, reducing caloric intake
• Slowing of gastric emptying, which prolongs satiety after meals
• Glucose-dependent stimulation of insulin secretion from pancreatic beta cells
• Glucose-dependent suppression of glucagon from pancreatic alpha cells

These effects are well-characterised in the extensive clinical literature for Ozempic and Wegovy.

Amylin Receptor Agonism (Cagrilintide Component)

Cagrilintide activates amylin receptors concentrated in the area postrema and hypothalamic nuclei involved in energy homeostasis. Research has investigated the amylin receptor system for its role in:

• Reducing meal size by promoting satiety signals from the hindbrain
• Slowing gastric emptying through a mechanism distinct from but overlapping with GLP-1 action
• Suppressing glucagon secretion in the postprandial state
• Modulating dopaminergic reward pathways associated with food-motivated behaviour

Native amylin acts in concert with insulin as part of the normal physiological response to food intake. Research has investigated amylin receptor agonism as a strategy to restore or amplify this satiety signal in the context of obesity, where amylin signalling may be blunted.

Dual Agonism: Rationale for Combination

GLP-1 receptors and amylin receptors are pharmacologically distinct and expressed in partially overlapping but non-identical neuronal populations. Research has investigated whether simultaneous activation of both systems produces additive or synergistic reductions in food intake beyond what either receptor agonist achieves alone.

The mechanistic rationale is supported by the observation that GLP-1 and amylin appear to act through complementary satiety circuits, such that engaging both pathways may reduce appetite through more complete coverage of the central energy-regulation network. Phase 2 clinical data, and subsequently Phase 3 data from the REDEFINE programme, are consistent with this hypothesis, showing greater weight reduction for the combination than for semaglutide 2.4 mg alone.

Reported Protocols

The following information represents commonly reported research ranges drawn from published clinical trial protocols and available literature. These are not medical recommendations.

Subcutaneous Administration

Subcutaneous injection is the only reported administration route for CagriSema. The combination is co-formulated for single weekly injection. Commonly reported doses in Phase 3 trials are cagrilintide 2.4 mg combined with semaglutide 2.4 mg per weekly injection.

• Frequency: Once weekly, on a consistent day each week
• Injection sites: Abdomen, thigh, or upper arm (subcutaneous); sites are rotated between injections to reduce local tissue response
• Target dose: 2.4 mg cagrilintide / 2.4 mg semaglutide per injection

Titration Schedule

A gradual dose escalation over approximately 16 weeks is the commonly reported approach in clinical trial protocols, designed to minimise gastrointestinal side effects during initiation. The titration mirrors the stepwise escalation used for Wegovy (semaglutide 2.4 mg) in approved clinical practice and reflects the tolerability profile of GLP-1 agonists as a class:

• Weeks 1 to 4: lower starting doses of both components
• Weeks 5 to 8: first dose increase
• Weeks 9 to 12: second dose increase
• Weeks 13 to 16: third dose increase, approaching target
• Week 17 onward: maintenance at the full 2.4 mg / 2.4 mg dose

Exact increments vary by specific trial protocol. The principle is consistent: slower escalation is associated with better gastrointestinal tolerability during initiation.

Phase 3 Data Context

The REDEFINE clinical trial programme represents the primary Phase 3 evidence base for CagriSema. The programme comprises multiple trials evaluating CagriSema in adults with obesity (body mass index 30 kg/m2 or above) or overweight with at least one weight-related comorbidity.

Key data points reported through 2025 and 2026 from the REDEFINE programme include:

• Approximately 22 to 25 percent mean body weight reduction over 68 weeks in trial participants receiving CagriSema, compared with lower reductions in comparator arms receiving semaglutide 2.4 mg alone or placebo
• Improvements in cardiometabolic markers including blood pressure, triglycerides, and glycaemic parameters in participants with type 2 diabetes
• A gastrointestinal adverse event profile consistent with other GLP-1 class agents, with the titration schedule reducing the incidence of early discontinuation

Earlier Phase 2 data (Frias et al., Lancet 2021) demonstrated approximately 15 percent body weight reduction with CagriSema at 32 weeks, compared with approximately 9 percent with semaglutide 2.4 mg alone in the same trial, providing the initial evidence of additive benefit that supported progression to Phase 3.

All data from the REDEFINE programme should be interpreted in the context of clinical trial conditions, including controlled settings, defined participant eligibility criteria, and concurrent lifestyle intervention components. Results from clinical trials may not generalise to all individual circumstances.

Reported Effects

The following effects have been reported in preclinical research, clinical trials, and anecdotal accounts. This list reflects the research landscape and does not constitute confirmed clinical outcomes for any specific individual.

Body Weight Reduction

Research has most consistently characterised CagriSema for body weight reduction in individuals with obesity or overweight. Phase 2 data demonstrated approximately 15 percent weight reduction at 32 weeks, exceeding the approximately 9 percent observed with semaglutide 2.4 mg alone. Phase 3 REDEFINE data indicate approximately 22 to 25 percent mean weight reduction over 68 weeks. The combination consistently outperforms semaglutide monotherapy in published trial data, consistent with the complementary dual-mechanism hypothesis.

Appetite Suppression

Research has reported reduced caloric intake and reduced appetite ratings in CagriSema trial participants, consistent with the combined GLP-1 and amylin receptor agonism targeting overlapping hypothalamic satiety circuits. Anecdotal accounts from research settings describe reduced food-motivated behaviour and earlier satiety with meals.

Glycaemic Effects

Research has investigated CagriSema in individuals with type 2 diabetes as part of the REDEFINE programme. Reported effects include reductions in fasting glucose, postprandial glucose excursions, and glycated haemoglobin (HbA1c), consistent with the glucose-dependent insulin secretion effects of the semaglutide component and the glucagon-suppressing effects of both components.

Cardiometabolic Markers

Reported effects in published trial data include reductions in systolic blood pressure, triglycerides, and waist circumference. These effects are consistent with class-level observations for GLP-1 agonists, with potential additional contributions from the amylin receptor agonism of cagrilintide.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following. This list does not constitute a comprehensive safety profile and should not be interpreted as predictive of individual outcomes.

The gastrointestinal side effect profile is the most prominent feature of CagriSema tolerability, consistent with the GLP-1 receptor agonist class. The dose-titration protocol used in clinical trials is designed specifically to reduce the incidence and severity of nausea and vomiting during initiation. Published trial data indicate that the overall tolerability profile is manageable in the majority of trial participants when titration is followed, with a minority of participants discontinuing due to gastrointestinal events.

An increased heart rate has been noted in the context of amylin receptor agonism; this is considered a class effect and has been observed in clinical trial data for CagriSema. The magnitude of this effect and its clinical significance continue to be characterised in the REDEFINE programme data.

The risk of cholelithiasis is consistent with observations across GLP-1 receptor agonist agents, attributed in part to reduced gallbladder motility and rapid weight loss.

Storage & Handling

Pre-Use Storage

CagriSema in clinical trial settings is formulated as a pre-filled pen injection device containing a solution for subcutaneous injection. Guidelines consistent with those for other GLP-1 class injectable agents apply:

• Refrigerator (2-8°C): Required storage condition; do not freeze
• Light sensitivity: Store in the original packaging to protect from light
• Room temperature: If temporarily removed from refrigeration, consistent with Wegovy guidance, storage below 30°C for up to 28 days has been described for the semaglutide 2.4 mg component in approved form; specific CagriSema handling guidance will be defined in product labelling upon approval

Handling Notes

• Do not use if the solution appears discoloured, cloudy, or contains visible particles
• Do not expose to heat or direct sunlight
• Once a dose has been administered, discard the needle; do not recap needles
• Dispose of pen devices and needles in accordance with local sharps disposal regulations

Research Peptide Context

For researchers working with investigational peptide components outside an approved formulation, general guidance for subcutaneous peptide solutions applies: refrigerate at 2-8°C, avoid freeze-thaw cycles once in solution, and consult the Reconstitution Guide for step-by-step preparation instructions.

Frequently Asked Questions

What is the difference between CagriSema and Ozempic or Wegovy? CagriSema is an investigational combination product consisting of two distinct active components: cagrilintide (a long-acting amylin analogue) and semaglutide 2.4 mg (the same molecule as Wegovy). Ozempic contains semaglutide 0.5 mg to 2 mg and is investigated primarily in the context of type 2 diabetes and cardiovascular risk. Wegovy contains semaglutide 2.4 mg and is approved for chronic weight management. CagriSema pairs the semaglutide 2.4 mg dose with cagrilintide 2.4 mg to activate both GLP-1 receptors and amylin receptors simultaneously, a dual mechanism not present in either Ozempic or Wegovy. Phase 2 data indicate that the combination produces greater body weight reduction than semaglutide 2.4 mg alone. As of 2026, CagriSema has not received regulatory approval for commercial use in any market.

What does the Phase 3 REDEFINE programme show for CagriSema? The REDEFINE programme is Novo Nordisk’s Phase 3 clinical trial series evaluating CagriSema in adults with obesity or overweight with weight-related comorbidities. Early data from the programme, reported through 2025 and 2026, indicate approximately 22 to 25 percent mean body weight reduction over 68 weeks in trial participants, compared with lower reductions observed in the semaglutide 2.4 mg alone arm. The programme also includes trials evaluating cardiovascular outcomes and effects in individuals with type 2 diabetes. Results continue to be published and analysed; Novo Nordisk has indicated regulatory filing is anticipated following completion of the programme. Individual trial identifiers include NCT04986943 and related registrations.

How does cagrilintide complement semaglutide mechanistically? Semaglutide activates glucagon-like peptide-1 (GLP-1) receptors in the hypothalamus and other brain regions, reducing appetite and slowing gastric emptying, with additional glucose-dependent effects on insulin secretion. Cagrilintide is a synthetic, long-acting amylin analogue that acts on amylin receptors (AMY1, AMY2, and AMY3), which are concentrated in the hypothalamus and area postrema. Amylin receptors and GLP-1 receptors are distinct receptor systems that converge on overlapping but non-identical appetite-regulating circuits. Research has investigated whether simultaneous activation of both receptor populations produces additive or synergistic reductions in food intake and body weight beyond what either agent achieves individually. Phase 2 data suggest the combination does produce greater weight reduction than semaglutide alone, which is consistent with the complementary receptor hypothesis.

Is CagriSema approved or available outside clinical trials? As of 2026, CagriSema has not received regulatory approval in any country. It is not approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), or equivalent authorities elsewhere. The compound exists in the research and development pipeline of Novo Nordisk, with Phase 3 REDEFINE trials ongoing. It is not commercially available. Individuals enrolled in clinical trials may receive it under the terms of those trials. Any product described as CagriSema available outside authorised trial settings would not have undergone the regulatory manufacturing, purity, and safety verification processes associated with approved medicines.

Related Pages

Goals: Metabolic Health | Fat Loss | Appetite & Weight Management

Class: GLP-1 Agonists

Comparisons: Retatrutide vs CagriSema

Also see: Semaglutide (the GLP-1 component of CagriSema, approved individually as Ozempic and Wegovy) | Tirzepatide (dual GIP/GLP-1 agonist; another investigational-to-approved dual mechanism weight-loss agent) | Retatrutide (triple GIP/GLP-1/glucagon agonist; investigational) | Liraglutide (earlier GLP-1 agonist; approved for weight management at 3 mg daily)

References & Further Reading

• Frias JP, et al. (2021). Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, active-controlled, double-blind, phase 2 trial. The Lancet, 397(10286), 2212-2224. PubMed →
• Enebo LB, et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for obesity (SCALE CAGRISEMA): a randomised, double-blind, controlled, phase 1b trial. The Lancet, 397(10286), 2199-2210. PubMed →
• Novo Nordisk. REDEFINE Phase 3 clinical trial programme. ClinicalTrials.gov identifier NCT04986943 and related registrations. ClinicalTrials.gov →
• Bhatt DL, et al. (2021). Amylin agonism in obesity: mechanistic rationale and clinical development context. Review context for amylin receptor biology.
• Drucker DJ. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740-756. PubMed →
• Larsen PJ, et al. (2010). Physiology of amylin and its pharmacological application. Background reference for amylin receptor biology underlying cagrilintide development.